Adynamic bone disease: an update and overview

Area of Science:

• Nephrology
• Endocrinology
• Bone Metabolism

Background:

• Adynamic bone disease (ABD) is a form of renal osteodystrophy.
• It is characterized by reduced osteoblast and osteoclast activity, leading to low bone turnover.
• ABD is prevalent in dialysis patients and those with chronic kidney disease (CKD) on conservative treatment.

Purpose of the Study:

• To explore the underlying mechanisms and implications of Adynamic Bone Disease (ABD) in chronic kidney disease (CKD).
• To investigate the relationship between parathyroid hormone (PTH) levels and bone turnover in uremic patients.
• To determine if ABD is a disease or a consequence of managing secondary hyperparathyroidism.

Main Methods:

• Review of existing literature on renal osteodystrophy and Adynamic Bone Disease (ABD).
• Analysis of the association between histological patterns of ABD and serum PTH levels in CKD patients.
• Consideration of theoretical factors contributing to skeletal resistance to PTH.

Main Results:

• ABD is histologically linked to low PTH levels, despite generally elevated PTH in CKD.
• Uremic bone tissue exhibits resistance to PTH, making it susceptible to low turnover states.
• Potential contributing factors include PTH receptor downregulation, increased osteoprotegerin, and altered bone morphogenetic proteins.

Conclusions:

• Adynamic bone disease (ABD) may be a consequence of over-treating secondary hyperparathyroidism rather than a distinct disease.
• It highlights the impaired ability of uremic bone to maintain normal turnover when PTH levels decrease.
• This condition underscores the complex bone-related complications in chronic kidney disease (CKD).